MJFF in the News

Denali Therapeutics announced plans on development of their LRRK2 compounds; preclinical work on the safety of these compounds was supported by the Foundation through a unique collaboration across several companies.

Catherine Kopil, PhD, director of research partnerships at MJFF, highlights the need to support neuroscientists who want to work outside the lab or clinic.

MJFF's online matching tool, Fox Trial Finder, is highlighted in a discussion of the accelerated enrollment of participants in the STEADY-PD III trial.

Michael J. Fox and MJFF CEO Todd Sherer, PhD, pen a commentary remembering Muhammad Ali. The opinion piece reflects on how we can collectively honor Ali's memory by curing Parkinson's.

Vice President of Medical Communications Rachel Dolhun, MD, provides background on Parkinson's symptoms and diagnosis for a story on the relationship between head trauma and the disease.

Foundation CEO Todd Sherer, PhD, comments on the connection between head injury and Parkinson's disease.

Rachel Dolhun, MD, movement disorder specialist and vice president of medical communications at MJFF, offers insight into Nuplazid (pimavanserin), a new drug indicated to treat Parkinson's disease psychosis.

On "Back to the Future Day," the White House invited Michael J. Fox to reflect on the progress and promise of Parkinson's disease research.